Eligibility for dapagliflozin and empagliflozin in a real-world heart failure population.

[1]  P. Ponikowski,et al.  Empagliflozin in Heart Failure with a Preserved Ejection Fraction. , 2021, The New England journal of medicine.

[2]  G. Filippatos,et al.  Evaluation of the effect of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR‐Reduced trial , 2019, European journal of heart failure.

[3]  Akshay S. Desai,et al.  Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus. , 2019, Circulation.

[4]  Akshay S. Desai,et al.  Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. , 2019, The New England journal of medicine.

[5]  L. Lund,et al.  The Swedish Heart Failure Registry: a living, ongoing quality assurance and research in heart failure , 2018, Upsala journal of medical sciences.

[6]  P. Ponikowski,et al.  Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. , 2020, The New England journal of medicine.

[7]  A. Kiss,et al.  Eligibility criteria of randomized controlled trials published in high-impact general medical journals: a systematic sampling review. , 2007, JAMA.

[8]  J. Ludvigsson,et al.  External review and validation of the Swedish national inpatient register , 2011, BMC public health.

[9]  C. Cannon,et al.  Efficacy of Ertugliflozin on Heart Failure–Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease , 2020, Circulation.

[10]  J. McMurray,et al.  How Should We Sequence the Treatments for Heart Failure and a Reduced Ejection Fraction? A Redefinition of Evidence-Based Medicine. , 2020, Circulation.

[11]  Gianluigi Savarese,et al.  A comprehensive population‐based characterization of heart failure with mid‐range ejection fraction , 2017, European journal of heart failure.

[12]  Deepak L. Bhatt,et al.  Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. , 2020, The New England journal of medicine.

[13]  S. Solomon,et al.  Applicability of US Food and Drug Administration Labeling for Dapagliflozin to Patients With Heart Failure With Reduced Ejection Fraction in US Clinical Practice: The Get With the Guidelines-Heart Failure (GWTG-HF) Registry. , 2020, JAMA cardiology.

[14]  B. Zinman,et al.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2015, The New England journal of medicine.

[15]  G. Filippatos,et al.  Evaluation of the effects of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR‐Preserved Trial , 2019, European journal of heart failure.

[16]  K. Mahaffey,et al.  Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events , 2017, Circulation.

[17]  C. Cannon,et al.  Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. , 2020, The New England journal of medicine.

[18]  Sanjiv J. Shah,et al.  Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial , 2021, European journal of heart failure.

[19]  P. Ponikowski,et al.  Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction. , 2021, JAMA cardiology.

[20]  S. Solomon,et al.  Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus , 2018, Circulation.

[21]  B. Zinman,et al.  Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial , 2016, European heart journal.

[22]  J. H. Patterson,et al.  Medical Therapy for Heart Failure With Reduced Ejection Fraction: The CHAMP-HF Registry. , 2018, Journal of the American College of Cardiology.

[23]  G. Filippatos,et al.  Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction , 2020, Circulation.

[24]  Akshay S. Desai,et al.  A trial to evaluate the effect of the sodium–glucose co‐transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA‐HF) , 2019, European journal of heart failure.

[25]  Declare–Timi Investigators.  Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes , 2019 .

[26]  P. Ponikowski,et al.  The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial , 2022, Nature Medicine.